comparemela.com

Latest Breaking News On - Martin bexon - Page 1 : comparemela.com

Form 6-K Medicenna Therapeutics For: Jun 22

Form 6-K Medicenna Therapeutics For: Jun 22
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLillian siuDavid mooneyKapil dhingraJohn sampsonBurkhard becherMedicenna superkinePeter lloydElizabeth williamsSergio quezadaHussein tawbiPaul smithWilliam redmondMartin bexonSuperkine immunotherapiesL bruce pearce

Medicenna Therapeutics Corp (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript

Medicenna Therapeutics Corp. (NASDAQ:NASDAQ:MDNA) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President.

United statesKumar rajaMatt bieglerDavid martinLiz williamsSwayampakula ramakanthMartin bexonShubhendu royDavid bautzAndre uddinCatherine novackCompany participantsCap researchDevelopment advisory committeeMackie research capitalMedicenna therapeutics corp

Medicenna Announces Management - GuruFocus com

GuruFocus Article or News written by GuruFocusNews and the topic is about:

United statesPaul smithMann muhsinPeter lloydElizabeth williamsMartin bexonSuperkine immunotherapiesBruce pearceL bruce pearceUniversity of new york at buffaloRegulatory affairsUniversity of newcastle upon tyneDevelopment advisory committeeMedicenna therapeutics corpExchange commissionChief medical officer

Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesPaul smithMann muhsinPeter lloydElizabeth williamsMartin bexonSuperkine immunotherapiesBruce pearceL bruce pearceUniversity of new york at buffaloAlfredp sloan foundationRegulatory affairsUniversity of newcastle upon tyneDevelopment advisory committeeHarvard medical schoolExchange commission

Medicenna Announces Management Change and Appoints

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose.

United statesPaul smithMann muhsinPeter lloydElizabeth williamsMartin bexonSuperkine immunotherapiesBruce pearceL bruce pearceUniversity of new york at buffaloAlfredp sloan foundationRegulatory affairsUniversity of newcastle upon tyneDevelopment advisory committeeHarvard medical schoolExchange commission

vimarsana © 2020. All Rights Reserved.